Nasdaq · CIK 0001490978
SDGR Schrodinger, Inc.
Insider trading from SEC Form 4. Last filing 21 d ago. Close $27.28 on Oct 9, 2026, +146% from the 52-week low and -16% from the high.
Last 90 days
Net insider value
-$928k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$928k by 1 insider
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
SDGROct 9, 2026 · close 27.28
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Schrodinger, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Karen Akinsanya See Remarks sell | $928k 31,599 shares | -31% | - | |
| 21Weak | Karen Akinsanya President of R&D, Therapeutics sell | $420k 16,723 shares | -52% | +56% from low0% from high | |
| 0Weak | Jenny Herman SVP & Controller sell | $14k 666 shares | -2% | - | |
| 13Weak | Robert Lorne Abel See Remarks sell | $32k 1,225 shares | -13% | - | |
| 3Weak | Jenny Herman SVP & Controller sell | $21k 859 shares | -5% | - | |
| 5Weak | Margaret Dugan Chief Medical Officer sell | $27k 1,531 shares | -10% | - |
Transactions
The last 48 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Karen Akinsanya See Remarks | MOption exercise Common Stock10b5-1 | +31,599 | $4.34 | $137k | 101,555 | 21 d ago |
| Sep 17, 2026 | Karen Akinsanya See Remarks | SOpen-market sale Common Stock10b5-1 | -10,000 | $28.00 | $280k | 91,555 | 21 d ago |
| Sep 17, 2026 | Karen Akinsanya See Remarks | SOpen-market sale Common Stock10b5-1 | -21,599 | $30.00 | $648k | 69,956 | 21 d ago |
| Sep 17, 2026 | Karen Akinsanya See Remarks | MOption exercise Stock Option (right to buy)derivative10b5-1 | -31,599 | $0.00 | $0 | 11,599 | 21 d ago |
| Jun 18, 2025 | Jeffrey Chodakewitz director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Richard Friesner director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 521,697 | Jun 20, 2025 |
| Jun 18, 2025 | Gary Sender director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Gary L Ginsberg director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Rosana Kapeller-Libermann director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Bridget A van Kralingen director | AGrant or award Common Stock | +1,499 | $0.00 | $0 | 11,499 | Jun 20, 2025 |
| Jun 18, 2025 | Michael Lynton director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Arun Oberoi director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Nancy Thornberry director | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | Michael Lynton director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Gary Sender director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Bridget A van Kralingen director | AGrant or award Stock Option (right to buy)derivative | +2,335 | $0.00 | $0 | 2,335 | Jun 20, 2025 |
| Jun 18, 2025 | Nancy Thornberry director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Arun Oberoi director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Rosana Kapeller-Libermann director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Gary L Ginsberg director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Jeffrey Chodakewitz director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 18, 2025 | Richard Friesner director | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| May 29, 2025 | Mannix Vartan Aklian See Remarks | AGrant or award Common Stock | +14,063 | $0.00 | $0 | 14,063 | May 29, 2025 |
| May 29, 2025 | Mannix Vartan Aklian See Remarks | AGrant or award Stock Option (right to buy)derivative | +84,375 | $0.00 | $0 | 84,375 | May 29, 2025 |
| May 21, 2025 | Rachit Jain EVP & CFO | AGrant or award Common Stock | +9,375 | $0.00 | $0 | 37,097 | May 22, 2025 |
| May 21, 2025 | Rachit Jain EVP & CFO | AGrant or award Stock Option (right to buy)derivative | +18,750 | $0.00 | $0 | 18,750 | May 22, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | MOption exercise Common Stock10b5-1 | +13,378 | $3.22 | $43k | 29,003 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | MOption exercise Common Stock10b5-1 | +3,345 | $2.92 | $9,767 | 32,348 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | SOpen-market sale Common Stock10b5-1 | -8,378 | $25.11 | $210k | 23,970 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | SOpen-market sale Common Stock10b5-1 | -5,000 | $25.11 | $126k | 18,970 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | SOpen-market sale Common Stock10b5-1 | -3,345 | $25.00 | $84k | 15,625 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | MOption exercise Stock Option (right to buy)derivative10b5-1 | -13,378 | $0.00 | $0 | 0 | Apr 15, 2025 |
| Apr 14, 2025 | Karen Akinsanya President of R&D, Therapeutics | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,345 | $0.00 | $0 | 0 | Apr 15, 2025 |
| Mar 6, 2025 | Jenny Herman SVP & Controller | SOpen-market sale Common Stock10b5-1 | -666 | $21.11 | $14k | 27,349 | Mar 7, 2025 |
| Mar 3, 2025 | Karen Akinsanya President of R&D, Therapeutics | AGrant or award Common Stock | +15,625 | $0.00 | $0 | 15,625 | Mar 4, 2025 |
| Mar 3, 2025 | Jenny Herman SVP & Controller | AGrant or award Common Stock | +9,800 | $0.00 | $0 | 28,015 | Mar 4, 2025 |
| Mar 3, 2025 | Ramy Farid President & CEO | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 221,932 | Mar 4, 2025 |
| Mar 3, 2025 | Margaret Dugan Chief Medical Officer | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 25,969 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Lorne Abel See Remarks | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 20,615 | Mar 4, 2025 |
| Mar 3, 2025 | Karen Akinsanya President of R&D, Therapeutics | AGrant or award Stock Option (right to buy)derivative | +62,500 | $0.00 | $0 | 62,500 | Mar 4, 2025 |
| Mar 3, 2025 | Margaret Dugan Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2025 |
| Mar 3, 2025 | Robert Lorne Abel See Remarks | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 4, 2025 |
| Mar 3, 2025 | Ramy Farid President & CEO | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 4, 2025 |
| Mar 3, 2025 | Jenny Herman SVP & Controller | AGrant or award Stock Option (right to buy)derivative | +8,400 | $0.00 | $0 | 8,400 | Mar 4, 2025 |
| Mar 3, 2025 | Ramy Farid President & CEO | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Mar 4, 2025 |
| Feb 11, 2025 | Jenny Herman SVP & Controller | SOpen-market sale Common Stock10b5-1 | -859 | $24.43 | $21k | 18,215 | Feb 12, 2025 |
| Feb 10, 2025 | Robert Lorne Abel See Remarks | SOpen-market sale Common Stock10b5-1 | -1,225 | $25.99 | $32k | 8,115 | Feb 12, 2025 |
| Oct 15, 2024 | Margaret Dugan Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,531 | $17.78 | $27k | 13,469 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Robert Lorne AbelSee Remarks
- Karen AkinsanyaPresident of R&D, Therapeutics
- Mannix Vartan AklianSee Remarks
- Jeffrey Chodakewitzdirector
- Margaret DuganChief Medical Officer
- Ramy FaridPresident & CEO
- Richard Friesnerdirector
- Gary L Ginsbergdirector
- Jenny HermanSVP & Controller
- Rachit JainEVP & CFO
- Rosana Kapeller-Libermanndirector
- Michael Lyntondirector
- Arun Oberoidirector
- Gary Senderdirector
- Nancy Thornberrydirector
- Bridget A van Kralingendirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.